Jasper Therapeutics (NASDAQ:JSPR – Get Free Report) released its quarterly earnings results on Monday. The company reported ($10.19) EPS for the quarter, missing the consensus estimate of ($1.77) by ($8.42), FiscalAI reports.
Jasper Therapeutics Price Performance
Shares of NASDAQ JSPR opened at $13.68 on Monday. The stock has a market capitalization of $15.16 million, a PE ratio of -0.29 and a beta of 3.30. The business has a fifty day moving average price of $16.79 and a two-hundred day moving average price of $24.15. Jasper Therapeutics has a fifty-two week low of $9.45 and a fifty-two week high of $72.60.
Analyst Ratings Changes
A number of equities analysts recently commented on JSPR shares. Piper Sandler began coverage on shares of Jasper Therapeutics in a research report on Wednesday, August 12th. They set an “overweight” rating and a $60.00 price target on the stock. HC Wainwright reissued a “buy” rating on shares of Jasper Therapeutics in a report on Tuesday, August 18th. Wall Street Zen lowered shares of Jasper Therapeutics from a “hold” rating to a “sell” rating in a research report on Saturday. Finally, William Blair initiated coverage on shares of Jasper Therapeutics in a research report on Wednesday, October 14th. They set an “outperform” rating on the stock. Four analysts have rated the stock with a Buy rating, three have issued a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, the stock has a consensus rating of “Hold” and an average target price of $220.00.
Check Out Our Latest Stock Analysis on Jasper Therapeutics
Jasper Therapeutics Company Profile
Jasper Therapeutics is a clinical-stage biotechnology company developing antibody-based therapies for conditions involving blood-forming stem cells and mast cells. Its research focuses on c-Kit, also known as CD117, a protein found on these cells. The company’s lead investigational drug, briquilimab (formerly JSP191), is a monoclonal antibody that targets c-Kit. Jasper has studied briquilimab as a conditioning treatment for stem cell transplantation and gene therapy, and is evaluating it for mast cell-mediated diseases, including chronic spontaneous urticaria.
Read More
- Five stocks we like better than Jasper Therapeutics
- 3 Large-Cap Stocks Are Outperforming the S&P 500 Without AI Hype
- Fossil Just Turned a Profit—Can Its Comeback Survive the Holidays?
- Beaming Up the Backlog: AeroVironment Lands $405M Laser Deal
- Intuitive Machines’ Business Is Taking Off—Will Its Stock Follow?
Receive News & Ratings for Jasper Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Jasper Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
